CJC-1295: clinical evidence record
Also known as: CJC-1295 with DAC, CJC-1295 without DAC, Modified GRF (1-29)
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-05-22
Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.
AI-friendly summary · CJC-1295
Developed by ConjuChem Inc in the 2000s. Phase 1 and Phase 2 human safety and pharmacokinetic work was conducted before commercial development paused. Sustained GH and IGF-1 elevation observed with the DAC variant in published trial work.
Mechanism of action
How CJC-1295 works
30-amino-acid synthetic analogue of growth-hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) variant uses a maleimidopropionic acid linker to covalently bind serum albumin, extending half-life from minutes to roughly 6 to 8 days in published preclinical and early-human work.
Top peer-reviewed citations
Selection of the most-cited peer-reviewed literature on CJC-1295. Where a verified PMID or DOI is shown, the citation links to the original record. Other citations list the title, authors, journal and year so the reader can locate the paper through the journal index or the PubMed search linked below. PeptideClear publishes editorial commentary, not clinical guidance.
-
Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295
Teichman SL, Neale A, Lawrence B, et al.. Journal of Clinical Endocrinology and Metabolism, 2006.
-
Pharmacokinetics and pharmacodynamics of CJC-1295
Ionescu M, Frohman LA. Journal of Clinical Endocrinology and Metabolism, 2006.
-
Sustained-release GHRH analogues and the GHRH receptor
Sackmann-Sala L, Berryman DE, Lubbers ER, List EO, Kopchick JJ. Growth Hormone and IGF Research, 2012.
-
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
Alba M, Fintini D, Sagazio A, et al.. American journal of physiology. Endocrinology and metabolism, 2006.
-
Advances in the detection of growth hormone releasing hormone synthetic analogs
Memdouh S, Gavrilović I, Ng K, et al.. Drug testing and analysis, 2021.
-
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
Coutinho LFD, DE Oliveira Neves LF, Camilo RP. The Journal of sports medicine and physical fitness, 2026.
-
Doping and sports endocrinology: growth hormone, IGF-1, insulin, and erythropoietin
García-Arnés JA, García-Casares N. Revista clinica espanola, 2023.
-
An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma
Timms M, Ganio K, Forbes G, et al.. Drug testing and analysis, 2019.
Full PubMed search: https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295+GHRH.
UK regulatory status
Plain-English summary of where CJC-1295 sits under the four UK and international frameworks that govern peptide supply. Editorial commentary, not legal advice.
- Misuse of Drugs Act 1971: Not controlled under the Misuse of Drugs Act 1971.
- Psychoactive Substances Act 2016: Not scheduled under the Psychoactive Substances Act 2016.
- MHRA medicines classification: No UK marketing authorisation as a medicine.
- WADA Prohibited List: WADA Prohibited List S2 (peptide hormones, growth factors), prohibited at all times.
Full regulatory record: CJC-1295 UK regulatory status.
Risks and unknowns
What the literature does not yet show about CJC-1295
Known concerns
- Most published efficacy claims for CJC-1295 require careful interpretation. Read the cited papers in full before drawing conclusions.
- Purity of UK research-peptide supply varies between retailers. Certificates of analysis and HPLC documentation differ.
- Cold-chain handling between manufacture and delivery is not standardised across the research-peptide market.
- Independent replication of single-group findings is the key check on any preclinical claim.
Open questions in the literature
- Where human pharmacokinetics have not been formally characterised, dose translation from animal models is not reliable.
- Long-term safety profile beyond the duration of published studies remains an open question.
- Interactions with other prescribed or unlicensed substances are typically not studied.
Regulatory note
No UK marketing authorisation as a medicine. Prohibited at all times under WADA S2 (peptide hormones, growth factors). The moment a UK seller or commentator makes a therapeutic claim, MHRA can treat the product as an unlicensed medicinal product.
Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.
Related reading on PeptideClear
Frequently asked questions
What is the evidence level for CJC-1295?
What is the UK regulatory status of CJC-1295?
Has CJC-1295 been tested in human clinical trials?
Where can I read the source literature for CJC-1295?
Last verified 2026-05-22. Editorial commentary, not legal or clinical advice. Citations without a linked identifier can be located through the PubMed search and the journal index.